BC Innovations | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
BC Innovations | Aug 29, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting S100A4 or depleting S100A4-expressing cells could help treat glioblastoma multiforme (GBM) and other gliomas. In samples from glioma patients, high tumor levels of...
BC Innovations | May 29, 2014
Targets & Mechanisms

S100A9-clot not, bleed not

Although the new generation of antithrombotic drugs provides marked improvements over warfarin, they all still carry bleeding risk. S100 calcium binding protein A9 could represent a new target that, when blocked, prevents thrombosis without increasing...
BC Innovations | Jan 30, 2014
Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Allergy; allergic rhinitis; atopic dermatitis S100 calcium binding protein A4 (S100A4) Human and mouse studies suggest inhibiting S100A4 could help treat...
Items per page:
1 - 4 of 4